Zhifeng Zhao

Dr. Zhifeng Zhao


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
LZLei Zheng
Lei Zheng
ZZZhifeng Zhao
Zhifeng Zhao
JLJiayun Lin
Jiayun Lin
HLHongjie Li
Hongjie Li
GWGuangbo Wu
Guangbo Wu
MLMeng Luo
Meng Luo

31 July 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ZZZhifeng Zhao
Zhifeng Zhao
QFQiang Fan
Qiang Fan
CZChihao Zhang
Chihao Zhang
LZLei Zheng
Lei Zheng
JLJiayun Lin
Jiayun Lin
MLMeng Luo
Meng Luo

13 December 2021 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
KWKe Wang
Ke Wang
YLYanzhen Lu
Yanzhen Lu
ZZZhifeng Zhao
Zhifeng Zhao
CZChihao Zhang
Chihao Zhang
Bioinformatics-Based Analysis of lncRNA-mRNA Interaction Network of Mild Hepatic Encephalopathy in Cirrhosis: Backgrounds. Serum long noncoding RNAs (lncRNAs) and messenger RNAs (mRNAs) interaction network was discovered to exert an important role in liver cirrhosis while little is known in mild hepatic encephalopathy (MHE). Therefore, we aim to systematically evaluate the serum lncRNA-mRNA network and its regulatory mechanism in MHE. Methods. The data of serum mRNAs and lncRNAs were derived from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) were calculated between 11 cirrhotic patients with and without MHE. Next, the biological functions and underlined pathways of DEGs were determined through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Finally, an interactive network between lncRNAs and mRNAs was built, and hub genes were identified, respectively. Results. A total of 64 differentially expressed lncRNAs (dif-lncRNAs) were found between patients with and without MHE, including 30 up- and 34 downregulated genes. 187 differentially expressed mRNAs (dif-mRNAs) were identified, including 84 up- and 103 downregulated genes. Functional enrichment analysis suggested that the regulatory pathways involved in MHE mainly consisted of a series of immune and inflammatory responses. Several hub mRNAs involved in regulatory network were identified, including CCL5, CCR5, CXCR3, CD274, STAT1, CXCR6, and EOMES. In addition, lnc-FAM84B-8 and lnc-SAMD3-1 were found to regulate these above hub genes through building a lncRNA-mRNA network. Conclusion. This is the first study to construct the serum lncRNA-mRNA network in MHE, demonstrating the critical role of lncRNAs in regulating inflammatory and immunological profiles in the developing of MHE, suggesting a latent mechanism in this pathophysiological process.

16 September 2025 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
ZZZhifeng Zhao
Zhifeng Zhao
BBBin Bai
Bin Bai
SWShiqi Wang
Shiqi Wang
YZYin Zhou
Yin Zhou
PYPengfei Yu
Pengfei Yu
BYBin Yang
Bin Yang

20 September 2023 in Heliyon
Verified
Journal Article
Open access
LLLi Li
Li Li
FLFeng Li
Feng Li
ZZZhifeng Zhao
Zhifeng Zhao
RXRongli Xie
Rongli Xie
DXDan Xu
Dan Xu
JFJian Fei
Jian Fei
To evaluate the long-term inhibition of malignant biliary tumor growth using paclitaxel (PTX)-covered polycaprolactone (PCL) electrospun membranes. A mixture of PCL, a material used to fabricate polymer stents, and PTX, a widely used chemotherapeutic agent, was synthesized by electrospinning. After preparing the drug-eluting membrane, drug release and fiber degradation were assessed in vitro under different pH conditions. The QBC939 cholangiocarcinoma cell line was cultured to establish a xenograft nude mouse model. Finally, the drug-eluting membrane was implanted into the mouse model, and the relative tumor inhibition rate was evaluated. A new PTX-loaded PCL electrospun fiber membrane was developed. The drug release rate was about 20–40% in the 32-day release cycle, and the release quantity was between 20 and 170 mg. As pH decreased, the release rate increased significantly. The degradation rate of the fiber membranes in vitro was approximately 20–48%, and was positively correlated with the drug loading rate. In animal experiments, the growth of tumors in mice was suppressed using drug-eluting membranes. The PTX-loaded PCL electrospun fiber membrane enhanced the long-term drug release and exhibited excellent antitumor effects in vivo.

11 July 2025 in JMIR Cancer
Verified
Journal Article
Open access
SWShiqi Wang
Shiqi Wang
NCNa Chai
Na Chai
JXJingji Xu
Jingji Xu
PYPengfei Yu
Pengfei Yu
LHLuguang Huang
Luguang Huang
MZMinwen Zheng
Minwen Zheng
Background: Immune checkpoint inhibitors represent an effective therapeutic approach for advanced gastric cancer. Their efficacy largely depends on the status of tumor biomarkers including human epidermal growth factor receptor 2 (HER2), programmed death-ligand 1 (PD-L1; combined positive score ≥1), and microsatellite instability-high (MSI-H). To noninvasively evaluate these biomarkers, researchers have developed radiomic models for individual biomarker prediction. However, in clinical practice, holistic prediction of these biomarkers as an integrated system is more efficient. Currently, the feasibility of implementing radiomics-based comprehensive biomarker prediction remains unclear, requiring further investigation. Objective: This study aimed to develop a radiomics-based predictive model using multiphase computed tomography (CT) images to holistically evaluate HER2, PD-L1, and MSI-H status in patients with gastric cancer. Methods: A retrospective analysis was conducted on 461 patients with gastric cancer who underwent radical gastrectomy between 2019 and 2022. Clinical data, contrast-enhanced CT images (arterial phase [AP] and portal venous phase [PP]), and pathological results were collected. Patients were categorized into two groups: (1) the programmed cell death protein-1 inhibitor panel-positive group, comprising patients with HER2 overexpression, PD-L1 positive, or MSI-H status; and (2) the negative group, comprising patients without HER2 amplification, PD-L1 negative, or microsatellite instability-low or microsatellite stable condition. Radiomic features (including first-order statistics, shape features, and wavelet-derived textures) were extracted from both AP and PP images, yielding 1834 features per phase. Least absolute shrinkage and selection operator regression was applied to select key features. In total, 3 models were constructed using the Extreme Gradient Boosting algorithm: AP-only (8 features), PP-only (22 features), and a fused model combining AP and PP features (20 features: 6 AP and 14 PP features). Model performance was evaluated using area under the curve (AUC), sensitivity, specificity, and decision curve analysis. Results: Of the 461 patients, 147 patients (31.9%) were classified into the panel-positive group. The clinical features were similar between the 2 groups. The fused model demonstrated superior performance in the test set (AUC 0.82, 95% CI 0.68‐0.95), significantly outperforming AP-only (AUC 0.61, 95% CI 0.47‐0.74) and PP-only models (AUC 0.70, 95% CI 0.49‐0.91). Sensitivity and specificity for the AP-only, PP-only, and the fused model were 0.33 and 0.85; 0.50 and 0.86; and 0.60 and 0.83, respectively. Decision curve analysis confirmed that the fused model provided higher clinical net benefit across threshold probabilities. Conclusions: The construction of integrated biomarker prediction models through radiomics demonstrates technical feasibility, offering a promising methodology for comprehensive tumor characterization.